Yizhen Fu

595 total citations
38 papers, 384 citations indexed

About

Yizhen Fu is a scholar working on Hepatology, Surgery and Oncology. According to data from OpenAlex, Yizhen Fu has authored 38 papers receiving a total of 384 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Hepatology, 18 papers in Surgery and 14 papers in Oncology. Recurrent topics in Yizhen Fu's work include Hepatocellular Carcinoma Treatment and Prognosis (30 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (17 papers) and Cancer Mechanisms and Therapy (9 papers). Yizhen Fu is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (30 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (17 papers) and Cancer Mechanisms and Therapy (9 papers). Yizhen Fu collaborates with scholars based in China, Sweden and United States. Yizhen Fu's co-authors include Yaojun Zhang, Minshan Chen, Zhongguo Zhou, Juncheng Wang, Yangxun Pan, Zili Hu, Jinbin Chen, Li Xu, Dandan Hu and Wei Peng and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Radiology.

In The Last Decade

Yizhen Fu

37 papers receiving 381 citations

Peers

Countries citing papers authored by Yizhen Fu

Since Specialization

Citations

This map shows the geographic impact of Yizhen Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yizhen Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yizhen Fu more than expected).

Fields of papers citing papers by Yizhen Fu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yizhen Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yizhen Fu. The network helps show where Yizhen Fu may publish in the future.

Co-authorship network of co-authors of Yizhen Fu

This figure shows the co-authorship network connecting the top 25 collaborators of Yizhen Fu. A scholar is included among the top collaborators of Yizhen Fu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yizhen Fu. Yizhen Fu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comparing PD‐L1 and PD‐1 inhibitors plus bevacizumab combined with hepatic arterial interventional therapies in unresetable hepatocellular carcinoma: A single‐center, real‐world study 2025 ·International Journal of Cancer ·(unknown), (unknown), (unknown), Jinbin Chen, Juncheng Wang, Yizhen Fu, Zili Hu, Meng Qi, Wenqing Gao, Dandan Hu, Yaojun Zhang, Yangxun Pan, Zhongguo Zhou	1
2	Neoadjuvant hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin for resectable single large hepatocellular carcinoma 2025 ·International Journal of Surgery ·Zili Hu, Min Deng, Yizhen Fu, Zhongguo Zhou, Huanwei Chen, Minshan Chen, Yao‐Jun Zhang	2
3	Transarterial Chemoembolization with Radiofrequency Ablation versus Surgical Resection for Small Late-Recurrence Hepatocellular Carcinoma 2025 ·Radiology ·Yaojun Zhang, Jinbin Chen, Zhongguo Zhou, Dandan Hu, Juncheng Wang, Yangxun Pan, Yizhen Fu, Zili Hu, Li Xu, MinShan Chen	3
4	Where Is the Future of Adjuvant Therapy for Hepatocellular Carcinoma? 2025 ·Journal of Clinical Oncology ·Yizhen Fu, Yaojun Zhang, Dandan Hu, Zhongguo Zhou, Li Xu, Minshan Chen	0
5	Transarterial therapy combined with bevacizumab plus immune checkpoint inhibitors as a neoadjuvant therapy for locally advanced HCC 2024 ·Frontiers in Immunology ·(unknown), Qianyu Wang, Hu Li, (unknown), Juncheng Wang, Dandan Hu, (unknown), Minshan Chen, Yao‐Jun Zhang, Yizhen Fu	1
6	Comparison of lenvatinib plus pembrolizumab versus first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma: a real-world retrospective study 2024 ·Frontiers in Immunology ·(unknown), (unknown), (unknown), Yizhen Fu, Zili Hu, Yangxun Pan, Juncheng Wang, Jinbin Chen, (unknown), Yao‐Jun Zhang, Minshan Chen, Dandan Hu	1
7	YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment 2024 ·Molecular Cancer ·(unknown), Xin Wang, Yizhen Fu, Weijie Wu, Zili Hu, Qingyang Lin, Wei Peng, Yangxun Pan, Juncheng Wang, Jinbin Chen, Dandan Hu, (unknown), Li Xu, Yaojun Zhang, Jiajie Hou, Minshan Chen	17
8	Comparison of resection, ablation, and stereotactic body radiation therapy in treating solitary hepatocellular carcinoma ≤5 cm: a retrospective, multicenter, cohort study 2024 ·International Journal of Surgery ·Yizhen Fu, (unknown), Shiliang Liu, Renguo Guan, (unknown), Jinbin Chen, Juncheng Wang, Yangxun Pan, Mengzhong Liu, Minshan Chen, Mian Xi, Yaojun Zhang	4
9	The Efficacy and Safety of Bevacizumab Plus Anti-PD-1/PD-L1 Inhibitors in Combination with Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular Carcinoma 2024 ·ImmunoTargets and Therapy ·(unknown), Jinbin Chen, Wei Peng, (unknown), Hu Li, (unknown), Yizhen Fu, Dandan Hu, Zhongguo Zhou, Minshan Chen, Yaojun Zhang, Juncheng Wang	2
10	Efficacy of additional locoregional therapy based on systemic therapy after intrahepatic progression for BCLC stage B/C hepatocellular carcinoma: A real-world study 2023 ·International Immunopharmacology ·Zili Hu, (unknown), (unknown), Weijie Wu, Zhongguo Zhou, Minshan Chen, Yizhen Fu, Yaojun Zhang	2
11	Laparoscopic Hepatectomy versus Open Hepatectomy After Conversion Therapy Using Transarterial Chemoembolization or Hepatic Arterial Infusion Chemotherapy for Patients with Initially Unresectable Hepatocellular Carcinoma 2023 ·Journal of Hepatocellular Carcinoma ·(unknown), Zili Hu, Yizhen Fu, Dandan Hu, Zhongguo Zhou, Minshan Chen, Yangxun Pan, Yaojun Zhang	1
12	Cholesterol and C-reactive protein prognostic score predicted prognosis of immune checkpoint inhibitors based interventional therapies for intermediate-to-advanced hepatocellular carcinoma patients 2023 ·International Immunopharmacology ·(unknown), (unknown), (unknown), Zili Hu, (unknown), Yizhen Fu, (unknown), (unknown), Juncheng Wang, Jinbin Chen, Dandan Hu, Zhongguo Zhou, Minshan Chen, Yaojun Zhang, Yangxun Pan	4
13	Size‐Tunable Nanoregulator‐Based Radiofrequency Ablation Suppresses MDSCs and Their Compensatory Immune Evasion in Hepatocellular Carcinoma 2023 ·Advanced Healthcare Materials ·Yuhao Tang, (unknown), Meiyan Zhu, Shuping Li, (unknown), Yizhen Fu, Zili Hu, (unknown), (unknown), Junbin Liao, (unknown), (unknown), Zhenwei Peng	15
14	Levels of pretreatment serum lipids predict responses to PD-1 inhibitor treatment in advanced intrahepatic cholangiocarcinoma 2023 ·International Immunopharmacology ·(unknown), (unknown), (unknown), Yizhen Fu, (unknown), Zili Hu, (unknown), Yangxun Pan, Yaojun Zhang, Zhongguo Zhou, Minshan Chen, Dandan Hu	11
15	Survival benefit of neoadjuvant hepatic arterial infusion chemotherapy followed by hepatectomy for hepatocellular carcinoma with portal vein tumor thrombus 2023 ·Frontiers in Pharmacology ·Zili Hu, (unknown), (unknown), Yizhen Fu, (unknown), Zhongguo Zhou, Minshan Chen, Yaojun Zhang	7
16	Comparison of hepatic arterial infusion chemotherapy with mFOLFOX vs. first-line systemic chemotherapy in patients with unresectable intrahepatic cholangiocarcinoma 2023 ·Frontiers in Pharmacology ·(unknown), Yizhen Fu, Weijie Wu, Zili Hu, Yangxun Pan, Juncheng Wang, Jinbin Chen, Dandan Hu, Zhongguo Zhou, Minshan Chen, Yaojun Zhang	9
17	Inflammation-Based Scores Predict Responses to PD-1 Inhibitor Treatment in Intrahepatic Cholangiocarcinoma 2022 ·Journal of Inflammation Research ·(unknown), (unknown), (unknown), Yizhen Fu, Zili Hu, Yangxun Pan, Jinbin Chen, Juncheng Wang, Yaojun Zhang, Zhongguo Zhou, Li Xu, Dandan Hu, Minshan Chen	20
18	Development and Validation of Prognostic Nomograms for Hepatocellular Carcinoma After Hepatectomy Based on Inflammatory Markers 2022 ·Journal of Hepatocellular Carcinoma ·Zili Hu, Yu Yuan, (unknown), Qingbo Liu, Yizhen Fu, (unknown), Xuqi Sun, Shaoqiang Li, (unknown), Minshan Chen	2
19	Intention to control low central venous pressure reduced blood loss during laparoscopic hepatectomy: A double-blind randomized clinical trial 2020 ·Surgery ·Yangxun Pan, Juncheng Wang, (unknown), Jinbin Chen, Wei He, Jiancong Chen, (unknown), Yizhen Fu, Xu Li, Yaojun Zhang, Minshan Chen, Renchun Lai, (unknown)	16
20	Stereotactic Body Radiotherapy vs. Radiofrequency Ablation in the Treatment of Hepatocellular Carcinoma: A Meta-Analysis 2020 ·Frontiers in Oncology ·Yangxun Pan, Yizhen Fu, Dandan Hu, Long Qian, Juncheng Wang, Mian Xi, Shiliang Liu, Li Xu, Mengzhong Liu, Minshan Chen, Yaojun Zhang	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact